SABSW — SAB Biotherapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1833214 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -23,377,000 | -22,491,000 | 238,210,000 | 8,267,000 | 23,425,000 |
| Mar 2026 | 0 | — | -19,997,736 | -18,868,885 | 248,470,498 | 20,519,724 | 21,222,197 |
| Dec 2025 | 0 | — | -15,770,231 | -16,860,743 | 172,809,969 | 10,502,680 | 21,315,594 |
| Sep 2025 | 0 | — | -12,678,969 | 45,445,469 | 183,448,368 | 29,424,708 | 18,374,019 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-53,937,111
Investing CF
$-202,106,130
Financing CF
$260,932,452
CapEx
$-2,624,377
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-152,255,000
Inventory
—
Receivables
$1,844,000
ST Investments
$94,365,000
EBIT TTM
$-12,543,660
Pretax Income TTM
$-12,775,159
Interest Exp TTM
$231,499
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -48,953,363 | 13,273,683 | 172,809,969 | 21,315,594 | 151,494,375 | -44,775,111 |
| Dec 2024 | 0 | -42,910,520 | -34,105,309 | 44,195,469 | 18,225,893 | 25,969,576 | -34,292,009 |
| Dec 2023 | 0 | -38,075,320 | -42,193,786 | 83,941,253 | 26,641,812 | 57,299,441 | -25,119,405 |
| Dec 2022 | 0 | -28,917,617 | -18,740,804 | 50,904,927 | 19,846,785 | 31,058,142 | -23,459,511 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $224.15B | $414.61 | — |
| GILD | GILEAD SCIENCES, INC. | $187.15B | $150.93 | — |
| MRNA | Moderna, Inc. | $79.40B | $198.88 | — |
| ARGX | ARGENX SE | $59.67B | $959.49 | — |
| RVMD | Revolution Medicines, Inc. | $43.93B | $204.97 | — |
News headlines (Yahoo Finance, 1h cache)
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress
2026-04-15 12:00 · Yahoo
SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes
2026-09-22 12:30 · Yahoo
SAB BIO to Participate in Upcoming Investor Conferences
2026-09-01 12:30 · Yahoo
SAB Biotherapeutics Q2 Earnings Call Highlights
2026-08-07 12:03 · Yahoo
SAB Biotherapeutics Inc (SABS) (Q2 2026) Earnings Call Highlights: Advancing SAB142 with Strong ...
2026-08-06 23:14 · Yahoo
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
2026-08-06 11:30 · Yahoo
SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET
2026-07-30 12:30 · Yahoo
SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment
2026-07-15 15:43 · Yahoo
Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
2026-07-07 12:00 · Yahoo
Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target?
2026-07-05 22:08 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.